BKD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Aftermarket And Service RevenueBruker’s installed base supports recurring consumables, software, and service revenue alongside capital equipment sales. This improves customer retention and creates a more durable revenue foundation than one-time instrument purchases alone.
Strong Bookings And Backlog HealthSustained bookings growth and a book-to-bill ratio above one indicate demand is exceeding current shipments and support future revenue visibility. Strength across scientific instruments and biopharma also broadens the recovery beyond one customer segment.
Margin Recovery And Cost SavingsImproved gross and operating margins, combined with executed cost reductions, can provide lasting operating leverage if demand stabilizes. Management’s additional 2027 savings target further supports potential profitability recovery and cash generation.
Bears Say
Severe Profitability DeteriorationThe move from sustained profits to losses shows that revenue growth has not translated into dependable earnings. Low current margins reduce resilience to cost, mix, or demand pressure and make the investment case dependent on successful operating recovery.
Regional And End-market WeaknessWeakness in China, broader APAC markets, and U.S. academic and government customers exposes Bruker to prolonged funding and capital-spending constraints. These end markets are important users of scientific instruments, so weakness can weigh on utilization and replacement demand.
Delayed Conversion Of Deep-tech BookingsStrong deep-tech and semiconductor orders do not convert quickly into reported revenue because of lengthy delivery cycles. This creates a persistent gap between demand signals and near-term sales, while requiring working capital and execution before the backlog produces earnings.
Bruker News
BKD FAQ
What was Bruker Corp’s price range in the past 12 months?
Currently, no data Available
What is Bruker Corp’s market cap?
Bruker Corp’s market cap is CHF6.96B.
When is Bruker Corp’s upcoming earnings report date?
Bruker Corp’s upcoming earnings report date is Oct 29, 2026 which is in 64 days.
How were Bruker Corp’s earnings last quarter?
Bruker Corp released its earnings results on Aug 04, 2026. The company reported CHF0.398 earnings per share for the quarter, beating the consensus estimate of CHF0.312 by CHF0.085.
Is Bruker Corp overvalued?
According to Wall Street analysts Bruker Corp’s price is currently Undervalued.
Does Bruker Corp pay dividends?
Bruker Corp does not currently pay dividends.
What is Bruker Corp’s EPS estimate?
Bruker Corp’s EPS estimate is 0.34.
How many shares outstanding does Bruker Corp have?
Currently, no data Available
What happened to Bruker Corp’s price movement after its last earnings report?
Bruker Corp reported an EPS of CHF0.398 in its last earnings report, beating expectations of CHF0.312. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Bruker Corp?
Currently, no hedge funds are holding shares in CH:BKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bruker Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF44.78 (― Upside)
CHF44.78 (― Upside)
Blogger Sentiment
Bullish
CH:BKD Sentiment 60%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth CHF160.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.53%
Trailing 12-Months
Company Description
Bruker Corp
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
BKD Company Deck
BKD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed material operational and financial progress — notably a return to organic growth in Q2, substantial margin expansion, double-digit non-GAAP EPS growth, strong deep-tech and semiconductor bookings, and confirmed cost-savings execution and year guidance. However, material lowlights included a $135M goodwill impairment leading to a GAAP loss, lingering weakness in U.S. academic/government spending, regional softness in China and APAC, timing-related revenue recognition delays from longer lead-time deep tech orders, and FX/tariff headwinds. On balance the positive momentum in bookings, margins, cash flow and cost savings, along with maintained FY guidance, outweigh the notable one-time impairment and near-term timing/currency headwinds.View all CH:BKD earnings summaries